In a report released yesterday, Matt Miksic from Credit Suisse maintained a Buy rating on Alcon (ALC – Research Report), with a price target of $96.00. The company’s shares closed last Thursday at $77.45.
According to TipRanks.com, Miksic is a 5-star analyst with an average return of 16.3% and a 73.1% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Vicarious Surgical, and Johnson & Johnson.
Alcon has an analyst consensus of Moderate Buy, with a price target consensus of $86.55, a 9.4% upside from current levels. In a report issued on February 16, BTIG also maintained a Buy rating on the stock with a $92.00 price target.
Based on Alcon’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.1 billion and net profit of $2 million. In comparison, last year the company earned revenue of $1.94 billion and had a net profit of $95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alcon Inc. is a medical company which is specialized in eye care products. The company develops, manufactures, distributes, and sells technologies and devices for cataract, retinal, refractive surgery, as well as contact lenses and lens care products.
Read More on ALC: